Mesotherapy

by | Apr 10, 2017

In France, a specialized natural pain relief therapy, known as Mesotherapy, is widely used for the treatment of many injuries and musculoskeletal aches and pains, sprains or strains, arthritis, TMJ, frozen shoulder and other common inflammatory conditions. Although it is not well known in the US, it’s renown is growing rapidly. It involves a local injection of homeopathic, natural and prescription medications into the mesoderm, as close to the site of injury as possible. It has been found to greatly improve circulation and nutrition to the affected area, as well as to provide exceptional analgesic, anti-inflammatory and muscle-relaxing benefits.

In sports medicine, it can greatly enhance healing and reduce recovery time, allowing athletes to get back into action as quickly as possible. Sports trauma is typically associated with significant soft tissue injuries, including ligaments, tendons and muscles. In most cases, the congestive and inflammatory reaction in these tissues is the major limiting factor in healing.

Oral anti-inflammatory and pain reducing drugs like Vioxx and Naprosin, have been shown to double the risk of heart attacks. These serious side effects, in addition to the well known tendency to cause internal bleeding, like Aspirin and Ibuprofen, highlights the need for doctors to offer patients safer alternatives. Mesotherapy is both safe and extremely effective.

Mesotherapy injectable medicines may include the following products:

  • Meadow saffron (Colchicum autumnale) is a plant based muscle relaxant used in Mesotherapy
  • Procaine or Lidocaine, which is an anesthetic that also softens hardened connective tissue and improves the diffusion of the other ingredients to key tissues.
  • An anti-inflammatory (Melilotus – a natural plant derived medicine, or Piroxicam, a Rx anti-inflammatory medicine)
  • Baclofen is a Rx injectable muscle relaxant that may be used in some cases
  • Vasodilators (Ginkgo biloba, Pentoxifyline)
  • Venous Congestion & Tissue Repair (Arnica, Hamamelis)
  • Collagen injectable liquid medical grade extract (porcine derived collagen made by by Guna of Italy)
  • These are injected into the mesoderm around the area to be treated, using the smallest needles. The syringe may contain 1ml to 30ml of medicine according to the area to be treated.

Mesotherapy can be used for the following indications:

  • Arthritis: Inflammation of a joint, such as degenerative joint disease (osteoarthritis) or auto-immune arthritis (rheumatoid arthritis).
  • Tendonitis: Inflammation of a tendon and/or peritendonitis
  • Frozen Shoulder: adhesive encapsulitis (hardened collagen connective tissue around the shouder joint)
  • Achilles tendinopathy, plantar fasciitis or extensor carpi ulnaris tendinopathy
  • Lateral or Medial meniscus tendonopathy
  • Muscle spasm: backache, torticollis or lumbago
  • TMJ Temporomandibular Joint Syndrome

Occasional Side-Effects: Digestive problems such as diarrhea and stomach pain.

Uncommon Side-Effects: Nausea and vomiting; Skin reactions such as itching, redness, pimples, blisters or bubbles on the skin.

The main two types of contra-indications are:

  • Known allergy to one of the injectable substances
  • Poor skin condition.

Treatment

On average, 6 to 10 injection points are used treatment area, introducing an average of 0.1 cc mixture. If the area to be treated is larger, more liquid is injected. After treatment, no cream or ice should be applied and no massage should be used. Three or four follow-up treatments are typically given commencing on the third, seventh, or fourteenth day after the first treatment. Usually 3-4 treatments provides dramatic healing resolution for acute conditions. Repeat treatments at 6-12 month intervals may be needed for more chronic conditions.

Tolerance and side-effects

Tolerance of the mesotherapy technique was examined in a French national study of 2,839 patients. Overall, tolerance of the technique was excellent. No anaphylactic or vagal shock was observed. Side-effects essentially involved the injection site. The most frequent side-effects included mild pain at the injection points, which was frequent but tolerable. Slight bruising was minimal and disappeared in a few days.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

5 + 6 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });